This company has been marked as potentially delisted and may not be actively trading. NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About Enfusion Stock (NYSE:ENFN) Get Enfusion alerts:Sign Up Key Stats Today's Range$10.76▼$10.7650-Day Range$10.85▼$10.8552-Week Range$7.83▼$11.80VolumeN/AAverage Volume735,304 shsMarket Capitalization$1.39 billionP/E Ratio269.07Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois. Read More Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENFN Stock News HeadlinesClearwater Analytics: Q3 Figures Show Enfusion Acquisition Brings Meaningful GrowthNovember 12, 2025 | seekingalpha.comClearwater Analytics reinstated with an Overweight at JPMorganApril 26, 2025 | markets.businessinsider.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.August 20 at 1:00 AM | The Oxford Club (Ad)Clearwater Analytics: 3 Acquisitions That Make This A Strong BuyApril 24, 2025 | seekingalpha.comClearwater Analytics Finalizes Acquisition of EnfusionApril 21, 2025 | businesswire.comClearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger ConsiderationApril 2, 2025 | businesswire.comENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFNApril 2, 2025 | businesswire.comEnfusion, Inc.: Enfusion Announces Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | finanznachrichten.deSee More Headlines ENFN Stock Analysis - Frequently Asked Questions How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) issued its quarterly earnings data on Monday, March, 3rd. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.02. The firm earned $52.94 million during the quarter, compared to analyst estimates of $53.98 million. Enfusion had a trailing twelve-month return on equity of 6.67% and a net margin of 1.70%. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. What other stocks do shareholders of Enfusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enfusion investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings3/03/2025Today8/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNYSE:ENFN CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees890Year Founded1997Profitability EPS (Trailing Twelve Months)$0.03 Trailing P/E Ratio269.07 Forward P/E Ratio179.33 P/E Growth1.85Net Income$6.03 million Net Margins1.70% Pretax Margin3.64% Return on Equity6.67% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$201.61 million Price / Sales6.88 Cash Flow$0.14 per share Price / Cash Flow78.75 Book Value$0.61 per share Price / Book17.64Miscellaneous Outstanding Shares129,001,000Free Float81,720,000Market Cap$1.39 billion OptionableNo Data Beta0.92 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NYSE:ENFN) was last updated on 8/20/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredShe passed the Series 7. Nobody taught her thisStephanie holds a Series 6 and Series 7, licensed to manage other people's money. Yet no exam ever taught her ...Jerremy Newsome | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
